Quantcast

Sedation – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Sedation
– Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Sedation – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Sedation (Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Sedation (Central Nervous System) pipeline guide also reviews of key
players involved in therapeutic development for Sedation and features
dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III and Preclinical stages are 3 and 3 respectively. Similarly,
the Universities portfolio in Preclinical stages comprises 1 molecules,
respectively.

Sedation (Central Nervous System) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Sedation (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Sedation (Central
    Nervous System) by companies and universities/research institutes
    based on information derived from company and industry-specific
    sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Sedation (Central
    Nervous System) therapeutics and enlists all their major and minor
    projects.
  • The pipeline guide evaluates Sedation (Central Nervous System)
    therapeutics based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Sedation (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Sedation (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Sedation (Central Nervous System) pipeline depth and focus of
    Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Drawbridge Pharmaceuticals Pty. Ltd.
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Jiangsu Nhwa Pharmaceutical Corp. Ltd.
  • Paion AG

Featured News & Press Releases

  • Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with
    Remimazolam in the U.S. As Sufficient; no Second Intranasal Study
    Required
  • Oct 18, 2017: Remimazolam phase III Broncoscopy data to be presented
    at the Chest Annual Meeting 2017
  • Sep 28, 2017: European Patent Office Grants Formulation Patent For
    Remimazolam In The EU
  • Jun 28, 2017: Paion reports positive headline data in U.S. Phase III
    trial with Remimazolam for procedural sedation undergoing Bronchoscopy
  • Mar 28, 2017: Paion successfully completes patient recruitment in U.S.
    Phase III study with Remimazolam for procedural sedation during
    Bronchoscopy
  • Mar 27, 2017: Paion reports positive headline data in U.S. Clinical
    safety trial of Remimazolam in high-risk patients undergoing
    colonoscopy
  • Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results
    Presented at the 2016 American College of Gastroenterology Annual
    Scientific Meeting
  • Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be
    Presented at the American College of Gastroenterology 2016 Meeting
  • Sep 06, 2016: PAION announces clinical development progress with
    remimazolam by its Partner Yichang Humanwell in China
  • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In
    Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
  • Apr 11, 2016: Paion Successfully Completes Patient Recruitment In
    Phase III Study With Remimazolam For Procedural Sedation During
    Colonoscopy
  • Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance
    Patent For Remimazolam Besylate
  • Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial
    In Cardiac Surgery Patients Due To Insufficient Recruitment
  • Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial
    of Remimazolam in High Risk Patients Undergoing Colonoscopy
  • Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority
    PMDA About Production Of Remimazolam For Japan

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fw7oxh

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Anesthetic
Drugs

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.